Pregnancy outcomes may be affected by psoriatic arthritis or antirheumatic treatment; registry cohort study shows that preterm birth and cesarean delivery were mostly increased by antirheumatic treatment, especially biologics.
A nationwide Swedish register studied 921 PsA-pregnancies
Read Article
Today I have a few questions: Is tramadol really a weak narcotic? Should we really still be doing placebo-controlled trials? What are we going to do about our patients who are smokers? This and more, in this week's review of the news and journal articles.
Read Article
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are among the most severe drug reactions, as they come with substantial mortality and morbidity. A review of European centers dealing with SJS and TEN shows that despite best treatment practices, the 6-week mortality rate was
Read Article
Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).
Read Article
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
Prior trials testing the utility of type I anti-CD20 antibody therapies - rituximab and
Read Article
Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).
Read Article
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.
Read Article
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
A randomized controlled trial has shown that treatment of plaque psoriasis via costimulatory blockade ( CD28/B7) with abatacept did not prevent psoriasis relapse after withdrawal of ustekinumab.
The purpose of this trial was to determine if abatacept (costimulatory blockade) after
Read Article
Patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) who were doing well on treatment with tumor necrosis factor (TNF) inhibitors were able to successfully taper the therapy when guided by disease activity, a retrospective cohort study found.
Read Article
Hepatitis B reactivation is an uncommon complication of biologic therapy use. Now, a serologic study of rheumatoid arthritis patients shows that HBV reactivation is seen with rituximab, and less so with abatacept, especially in patients without hepatitis B antibody (HBsAb) positivity.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
October 8, 2021 the U.S. Food and Drug Administration (FDA) approved avacopan (trade name: Taveneos), an oral complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis). It is
Read Article
Arthritis numbers are rising, and people are finally talking about osteoarthritis. Also, ACR 2021 is just a few weeks away - are you ready? Finally, I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
The #1 question I get from new consults: “How did I get arthritis?” Here is my list of 11 drugs (or drug classes) known to cause arthritis or rheumatic disorders (as an unintended consequence). #RheumNow https://t.co/GsV0Qj9ENr https://t.co/IrTkY5yFdY
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
Discussions on drug safety can be as treacherous as quicksand for the patient and physician. What the physician knows and what the patient perceives may not be in sync.
Read Post
